Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000723526 | SCV000110803 | pathogenic | not provided | 2012-07-10 | criteria provided, single submitter | clinical testing | |
Neurometabolisches Labor, |
RCV000078942 | SCV000586685 | pathogenic | Metachromatic leukodystrophy | 2017-05-01 | criteria provided, single submitter | research | |
Counsyl | RCV000078942 | SCV000788912 | likely pathogenic | Metachromatic leukodystrophy | 2016-12-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000078942 | SCV001203142 | pathogenic | Metachromatic leukodystrophy | 2023-12-06 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Tyr65*) in the ARSA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ARSA are known to be pathogenic (PMID: 8962139, 10477432). This variant is present in population databases (rs398123414, gnomAD 0.002%). This premature translational stop signal has been observed in individuals with metachromatic leukodystrophy (PMID: 24001781, 28762252). This variant is also known as 189delC, Y63X. ClinVar contains an entry for this variant (Variation ID: 93121). For these reasons, this variant has been classified as Pathogenic. |
Natera, |
RCV000078942 | SCV002083908 | pathogenic | Metachromatic leukodystrophy | 2020-08-20 | no assertion criteria provided | clinical testing |